Effect of Para-Aminobenzoic Acid on the Course of Retinal Degeneration in the rd10 Mouse

Recent evidence suggests that oxidative injury plays a significant role in the pathogenesis of retinal degenerative diseases. Para-aminobenzoic acid (PABA) is a cyclic amino acid, which may act to decrease lipid peroxidation and oxidative injury. Our aim was to evaluate the efficacy of PABA in atten...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of ocular pharmacology and therapeutics 2009-12, Vol.25 (6), p.475-482
Hauptverfasser: GALBINUR, Tural, OBOLENSKY, Alexey, BERENSHTEIN, Eduard, VINOKUR, Vladimir, CHOWERS, Itay, CHEVION, Mordechai, BANIN, Eyal
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 482
container_issue 6
container_start_page 475
container_title Journal of ocular pharmacology and therapeutics
container_volume 25
creator GALBINUR, Tural
OBOLENSKY, Alexey
BERENSHTEIN, Eduard
VINOKUR, Vladimir
CHOWERS, Itay
CHEVION, Mordechai
BANIN, Eyal
description Recent evidence suggests that oxidative injury plays a significant role in the pathogenesis of retinal degenerative diseases. Para-aminobenzoic acid (PABA) is a cyclic amino acid, which may act to decrease lipid peroxidation and oxidative injury. Our aim was to evaluate the efficacy of PABA in attenuating oxidative injury and rate of retinal degeneration in the rd10 mouse. PABA (50 mg/kg) was administered intraperitoneally six times per week in 28 rd10 mice from postnatal day 3. Twenty-four littermate control mice were similarly injected with saline. At 3, 4.5, and 6 weeks of age, electrophysiological (full field electroretinogram-ERG), quantitative histological, and immunohistochemical techniques were used to assess the course and extent of retinal degeneration. Degree of lipid peroxidation was determined by the measurement of thiobarbituric acid reactive species (TBARS) and retinal carbonyl content was quantified using the 2,4-dinitrophenylhydrazine method. Dark adapted mixed rod-cone ERG responses at 3 weeks of age were higher in the PABA-treated group as compared to saline control (P < 0.05). By 4.5 weeks, this protective effect was largely abolished and by 6 weeks ERG was unrecordable in both groups. However, at both 3 and 4.5 weeks of age, light-adapted cone ERG amplitudes were better preserved in PABA-treated animals. At 4.5 weeks, thickness of the outer nuclear layer was 28.6% higher in the peripheral retina of PABA-treated mice as compared to controls (P < 0.05). Quantitative immunohistochemistry revealed 2.4-fold higher red/green cone opsin content in the retinas of PABA-treated mice (P < 0.005). At both 3 and 4.5 weeks, levels of TBARS and protein carbonyls were 49%-69% lower in PABA-treated retinas (P < 0.05-0.0005), suggesting less oxidative injury. PABA treatment may protect retinal function and attenuate the course of retinal degeneration in rd10 mice. Biochemical parameters indicate a lower degree of oxidative injury in PABA-treated retinas. PABA may potentially serve as an addition to antioxidative treatment for retinal and macular degenerations.
doi_str_mv 10.1089/jop.2009.0020
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733681742</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733681742</sourcerecordid><originalsourceid>FETCH-LOGICAL-c322t-fdb7a8aa928da6ba88ecf5ba8afcdf3181e0f0052698955b365789d1c5a1bb463</originalsourceid><addsrcrecordid>eNpF0D1PwzAQgGELgShfIyvKgphSznadOGNVPiUQCIHEFl2cMxilcbHTAX49rlpgOg_PnayXsWMOYw66Ov_wi7EAqMYAArbYHleqzMtSiu30Bg15WWg5YvsxfgBwCQXfZaO0ILRQxR57vbSWzJB5mz1iwHw6d71vqP_2zmRT49rM99nwTtnML0OklXuiwfXYZRf0Rj0FHFwibq1CyyG798tIh2zHYhfpaDMP2MvV5fPsJr97uL6dTe9yI4UYcts2JWrESugWiwa1JmNVmmhNayXXnMACKFFUulKqkYUqddVyo5A3zaSQB-xsfXcR_OeS4lDPXTTUddhT-kddSlloXk5EkvlamuBjDGTrRXBzDF81h3rVsk4t61XLetUy-ZPN5WUzp_ZP_8ZL4HQDMBrsbMDeuPjvhNASFMgfrWF7ng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733681742</pqid></control><display><type>article</type><title>Effect of Para-Aminobenzoic Acid on the Course of Retinal Degeneration in the rd10 Mouse</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>GALBINUR, Tural ; OBOLENSKY, Alexey ; BERENSHTEIN, Eduard ; VINOKUR, Vladimir ; CHOWERS, Itay ; CHEVION, Mordechai ; BANIN, Eyal</creator><creatorcontrib>GALBINUR, Tural ; OBOLENSKY, Alexey ; BERENSHTEIN, Eduard ; VINOKUR, Vladimir ; CHOWERS, Itay ; CHEVION, Mordechai ; BANIN, Eyal</creatorcontrib><description>Recent evidence suggests that oxidative injury plays a significant role in the pathogenesis of retinal degenerative diseases. Para-aminobenzoic acid (PABA) is a cyclic amino acid, which may act to decrease lipid peroxidation and oxidative injury. Our aim was to evaluate the efficacy of PABA in attenuating oxidative injury and rate of retinal degeneration in the rd10 mouse. PABA (50 mg/kg) was administered intraperitoneally six times per week in 28 rd10 mice from postnatal day 3. Twenty-four littermate control mice were similarly injected with saline. At 3, 4.5, and 6 weeks of age, electrophysiological (full field electroretinogram-ERG), quantitative histological, and immunohistochemical techniques were used to assess the course and extent of retinal degeneration. Degree of lipid peroxidation was determined by the measurement of thiobarbituric acid reactive species (TBARS) and retinal carbonyl content was quantified using the 2,4-dinitrophenylhydrazine method. Dark adapted mixed rod-cone ERG responses at 3 weeks of age were higher in the PABA-treated group as compared to saline control (P &lt; 0.05). By 4.5 weeks, this protective effect was largely abolished and by 6 weeks ERG was unrecordable in both groups. However, at both 3 and 4.5 weeks of age, light-adapted cone ERG amplitudes were better preserved in PABA-treated animals. At 4.5 weeks, thickness of the outer nuclear layer was 28.6% higher in the peripheral retina of PABA-treated mice as compared to controls (P &lt; 0.05). Quantitative immunohistochemistry revealed 2.4-fold higher red/green cone opsin content in the retinas of PABA-treated mice (P &lt; 0.005). At both 3 and 4.5 weeks, levels of TBARS and protein carbonyls were 49%-69% lower in PABA-treated retinas (P &lt; 0.05-0.0005), suggesting less oxidative injury. PABA treatment may protect retinal function and attenuate the course of retinal degeneration in rd10 mice. Biochemical parameters indicate a lower degree of oxidative injury in PABA-treated retinas. PABA may potentially serve as an addition to antioxidative treatment for retinal and macular degenerations.</description><identifier>ISSN: 1080-7683</identifier><identifier>EISSN: 1557-7732</identifier><identifier>DOI: 10.1089/jop.2009.0020</identifier><identifier>PMID: 20028256</identifier><language>eng</language><publisher>Larchmont, NY: Liebert</publisher><subject>4-Aminobenzoic Acid - pharmacology ; Animals ; Antioxidants - pharmacology ; Biological and medical sciences ; Diseases of the skin. Cosmetics ; Electrophysiology ; Injections, Intraperitoneal ; Lipid Peroxidation - drug effects ; Medical sciences ; Mice ; Mice, Inbred C57BL ; Ophthalmology ; Oxidative Stress - drug effects ; Pharmacology. Drug treatments ; Protein Carbonylation - drug effects ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Retinal Degeneration - physiopathology ; Retinal Degeneration - prevention &amp; control ; Retinopathies ; Thiobarbituric Acid Reactive Substances - metabolism</subject><ispartof>Journal of ocular pharmacology and therapeutics, 2009-12, Vol.25 (6), p.475-482</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c322t-fdb7a8aa928da6ba88ecf5ba8afcdf3181e0f0052698955b365789d1c5a1bb463</citedby><cites>FETCH-LOGICAL-c322t-fdb7a8aa928da6ba88ecf5ba8afcdf3181e0f0052698955b365789d1c5a1bb463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22283050$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20028256$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GALBINUR, Tural</creatorcontrib><creatorcontrib>OBOLENSKY, Alexey</creatorcontrib><creatorcontrib>BERENSHTEIN, Eduard</creatorcontrib><creatorcontrib>VINOKUR, Vladimir</creatorcontrib><creatorcontrib>CHOWERS, Itay</creatorcontrib><creatorcontrib>CHEVION, Mordechai</creatorcontrib><creatorcontrib>BANIN, Eyal</creatorcontrib><title>Effect of Para-Aminobenzoic Acid on the Course of Retinal Degeneration in the rd10 Mouse</title><title>Journal of ocular pharmacology and therapeutics</title><addtitle>J Ocul Pharmacol Ther</addtitle><description>Recent evidence suggests that oxidative injury plays a significant role in the pathogenesis of retinal degenerative diseases. Para-aminobenzoic acid (PABA) is a cyclic amino acid, which may act to decrease lipid peroxidation and oxidative injury. Our aim was to evaluate the efficacy of PABA in attenuating oxidative injury and rate of retinal degeneration in the rd10 mouse. PABA (50 mg/kg) was administered intraperitoneally six times per week in 28 rd10 mice from postnatal day 3. Twenty-four littermate control mice were similarly injected with saline. At 3, 4.5, and 6 weeks of age, electrophysiological (full field electroretinogram-ERG), quantitative histological, and immunohistochemical techniques were used to assess the course and extent of retinal degeneration. Degree of lipid peroxidation was determined by the measurement of thiobarbituric acid reactive species (TBARS) and retinal carbonyl content was quantified using the 2,4-dinitrophenylhydrazine method. Dark adapted mixed rod-cone ERG responses at 3 weeks of age were higher in the PABA-treated group as compared to saline control (P &lt; 0.05). By 4.5 weeks, this protective effect was largely abolished and by 6 weeks ERG was unrecordable in both groups. However, at both 3 and 4.5 weeks of age, light-adapted cone ERG amplitudes were better preserved in PABA-treated animals. At 4.5 weeks, thickness of the outer nuclear layer was 28.6% higher in the peripheral retina of PABA-treated mice as compared to controls (P &lt; 0.05). Quantitative immunohistochemistry revealed 2.4-fold higher red/green cone opsin content in the retinas of PABA-treated mice (P &lt; 0.005). At both 3 and 4.5 weeks, levels of TBARS and protein carbonyls were 49%-69% lower in PABA-treated retinas (P &lt; 0.05-0.0005), suggesting less oxidative injury. PABA treatment may protect retinal function and attenuate the course of retinal degeneration in rd10 mice. Biochemical parameters indicate a lower degree of oxidative injury in PABA-treated retinas. PABA may potentially serve as an addition to antioxidative treatment for retinal and macular degenerations.</description><subject>4-Aminobenzoic Acid - pharmacology</subject><subject>Animals</subject><subject>Antioxidants - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Diseases of the skin. Cosmetics</subject><subject>Electrophysiology</subject><subject>Injections, Intraperitoneal</subject><subject>Lipid Peroxidation - drug effects</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Ophthalmology</subject><subject>Oxidative Stress - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Carbonylation - drug effects</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Retinal Degeneration - physiopathology</subject><subject>Retinal Degeneration - prevention &amp; control</subject><subject>Retinopathies</subject><subject>Thiobarbituric Acid Reactive Substances - metabolism</subject><issn>1080-7683</issn><issn>1557-7732</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0D1PwzAQgGELgShfIyvKgphSznadOGNVPiUQCIHEFl2cMxilcbHTAX49rlpgOg_PnayXsWMOYw66Ov_wi7EAqMYAArbYHleqzMtSiu30Bg15WWg5YvsxfgBwCQXfZaO0ILRQxR57vbSWzJB5mz1iwHw6d71vqP_2zmRT49rM99nwTtnML0OklXuiwfXYZRf0Rj0FHFwibq1CyyG798tIh2zHYhfpaDMP2MvV5fPsJr97uL6dTe9yI4UYcts2JWrESugWiwa1JmNVmmhNayXXnMACKFFUulKqkYUqddVyo5A3zaSQB-xsfXcR_OeS4lDPXTTUddhT-kddSlloXk5EkvlamuBjDGTrRXBzDF81h3rVsk4t61XLetUy-ZPN5WUzp_ZP_8ZL4HQDMBrsbMDeuPjvhNASFMgfrWF7ng</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>GALBINUR, Tural</creator><creator>OBOLENSKY, Alexey</creator><creator>BERENSHTEIN, Eduard</creator><creator>VINOKUR, Vladimir</creator><creator>CHOWERS, Itay</creator><creator>CHEVION, Mordechai</creator><creator>BANIN, Eyal</creator><general>Liebert</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20091201</creationdate><title>Effect of Para-Aminobenzoic Acid on the Course of Retinal Degeneration in the rd10 Mouse</title><author>GALBINUR, Tural ; OBOLENSKY, Alexey ; BERENSHTEIN, Eduard ; VINOKUR, Vladimir ; CHOWERS, Itay ; CHEVION, Mordechai ; BANIN, Eyal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c322t-fdb7a8aa928da6ba88ecf5ba8afcdf3181e0f0052698955b365789d1c5a1bb463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>4-Aminobenzoic Acid - pharmacology</topic><topic>Animals</topic><topic>Antioxidants - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Diseases of the skin. Cosmetics</topic><topic>Electrophysiology</topic><topic>Injections, Intraperitoneal</topic><topic>Lipid Peroxidation - drug effects</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Ophthalmology</topic><topic>Oxidative Stress - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Carbonylation - drug effects</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Retinal Degeneration - physiopathology</topic><topic>Retinal Degeneration - prevention &amp; control</topic><topic>Retinopathies</topic><topic>Thiobarbituric Acid Reactive Substances - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GALBINUR, Tural</creatorcontrib><creatorcontrib>OBOLENSKY, Alexey</creatorcontrib><creatorcontrib>BERENSHTEIN, Eduard</creatorcontrib><creatorcontrib>VINOKUR, Vladimir</creatorcontrib><creatorcontrib>CHOWERS, Itay</creatorcontrib><creatorcontrib>CHEVION, Mordechai</creatorcontrib><creatorcontrib>BANIN, Eyal</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of ocular pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GALBINUR, Tural</au><au>OBOLENSKY, Alexey</au><au>BERENSHTEIN, Eduard</au><au>VINOKUR, Vladimir</au><au>CHOWERS, Itay</au><au>CHEVION, Mordechai</au><au>BANIN, Eyal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Para-Aminobenzoic Acid on the Course of Retinal Degeneration in the rd10 Mouse</atitle><jtitle>Journal of ocular pharmacology and therapeutics</jtitle><addtitle>J Ocul Pharmacol Ther</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>25</volume><issue>6</issue><spage>475</spage><epage>482</epage><pages>475-482</pages><issn>1080-7683</issn><eissn>1557-7732</eissn><abstract>Recent evidence suggests that oxidative injury plays a significant role in the pathogenesis of retinal degenerative diseases. Para-aminobenzoic acid (PABA) is a cyclic amino acid, which may act to decrease lipid peroxidation and oxidative injury. Our aim was to evaluate the efficacy of PABA in attenuating oxidative injury and rate of retinal degeneration in the rd10 mouse. PABA (50 mg/kg) was administered intraperitoneally six times per week in 28 rd10 mice from postnatal day 3. Twenty-four littermate control mice were similarly injected with saline. At 3, 4.5, and 6 weeks of age, electrophysiological (full field electroretinogram-ERG), quantitative histological, and immunohistochemical techniques were used to assess the course and extent of retinal degeneration. Degree of lipid peroxidation was determined by the measurement of thiobarbituric acid reactive species (TBARS) and retinal carbonyl content was quantified using the 2,4-dinitrophenylhydrazine method. Dark adapted mixed rod-cone ERG responses at 3 weeks of age were higher in the PABA-treated group as compared to saline control (P &lt; 0.05). By 4.5 weeks, this protective effect was largely abolished and by 6 weeks ERG was unrecordable in both groups. However, at both 3 and 4.5 weeks of age, light-adapted cone ERG amplitudes were better preserved in PABA-treated animals. At 4.5 weeks, thickness of the outer nuclear layer was 28.6% higher in the peripheral retina of PABA-treated mice as compared to controls (P &lt; 0.05). Quantitative immunohistochemistry revealed 2.4-fold higher red/green cone opsin content in the retinas of PABA-treated mice (P &lt; 0.005). At both 3 and 4.5 weeks, levels of TBARS and protein carbonyls were 49%-69% lower in PABA-treated retinas (P &lt; 0.05-0.0005), suggesting less oxidative injury. PABA treatment may protect retinal function and attenuate the course of retinal degeneration in rd10 mice. Biochemical parameters indicate a lower degree of oxidative injury in PABA-treated retinas. PABA may potentially serve as an addition to antioxidative treatment for retinal and macular degenerations.</abstract><cop>Larchmont, NY</cop><pub>Liebert</pub><pmid>20028256</pmid><doi>10.1089/jop.2009.0020</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1080-7683
ispartof Journal of ocular pharmacology and therapeutics, 2009-12, Vol.25 (6), p.475-482
issn 1080-7683
1557-7732
language eng
recordid cdi_proquest_miscellaneous_733681742
source MEDLINE; Alma/SFX Local Collection
subjects 4-Aminobenzoic Acid - pharmacology
Animals
Antioxidants - pharmacology
Biological and medical sciences
Diseases of the skin. Cosmetics
Electrophysiology
Injections, Intraperitoneal
Lipid Peroxidation - drug effects
Medical sciences
Mice
Mice, Inbred C57BL
Ophthalmology
Oxidative Stress - drug effects
Pharmacology. Drug treatments
Protein Carbonylation - drug effects
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Retinal Degeneration - physiopathology
Retinal Degeneration - prevention & control
Retinopathies
Thiobarbituric Acid Reactive Substances - metabolism
title Effect of Para-Aminobenzoic Acid on the Course of Retinal Degeneration in the rd10 Mouse
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T12%3A24%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Para-Aminobenzoic%20Acid%20on%20the%20Course%20of%20Retinal%20Degeneration%20in%20the%20rd10%20Mouse&rft.jtitle=Journal%20of%20ocular%20pharmacology%20and%20therapeutics&rft.au=GALBINUR,%20Tural&rft.date=2009-12-01&rft.volume=25&rft.issue=6&rft.spage=475&rft.epage=482&rft.pages=475-482&rft.issn=1080-7683&rft.eissn=1557-7732&rft_id=info:doi/10.1089/jop.2009.0020&rft_dat=%3Cproquest_cross%3E733681742%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733681742&rft_id=info:pmid/20028256&rfr_iscdi=true